Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Change in Cash (2016 - 2025)

Moleculin Biotech's Change in Cash history spans 10 years, with the latest figure at $2.2 million for Q4 2025.

  • Quarterly results put Change in Cash at $2.2 million for Q4 2025, up 142.42% from a year ago — trailing twelve months through Dec 2025 was $4.6 million (up 123.87% YoY), and the annual figure for FY2025 was $4.6 million, up 123.87%.
  • Change in Cash for Q4 2025 was $2.2 million at Moleculin Biotech, up from -$854000.0 in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $71.1 million in Q1 2021 to a low of -$8.1 million in Q2 2022.
  • The 5-year median for Change in Cash is -$4.9 million (2022), against an average of -$314750.0.
  • The sharpest move saw Change in Cash soared 7681.18% in 2021, then plummeted 398.25% in 2024.
  • Year by year, Change in Cash stood at -$4.3 million in 2021, then tumbled by 69.52% to -$7.2 million in 2022, then skyrocketed by 85.8% to -$1.0 million in 2023, then tumbled by 398.25% to -$5.1 million in 2024, then soared by 142.42% to $2.2 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $2.2 million, -$854000.0, and -$159000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.